248
Views
8
CrossRef citations to date
0
Altmetric
Clinical Focus: Diabetes - Original Research

Statin-induced new onset of diabetes in dyslipidemic patients: a retrospective study

, , , ORCID Icon &
Pages 383-387 | Received 16 Apr 2019, Accepted 11 Jul 2019, Published online: 05 Aug 2019

References

  • Beltowski J, Wojcicka G, Jamroz-Wisniewska A. Adverse effects of statins- mechanisms and consequences. Curr Drug Saf. 2009;4:209–228.
  • Zaharan NL, Williams D, Bennett K. Statins and risk of treated incident diabetes in a primary care population. Br J Clin Pharmacol. 2013;75:1118–1124.
  • Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in post-menopausal women in the women’s health initiative. JAMA. 2012;172:144–152.
  • Navarese EP, Szczesniak A, Kolodziejczak M, et al. Statins and Risk of New-Onset Diabetes Mellitus: is there a Rationale for Individualized Statin Therapy? Am J Cardiovasc Drugs. 2014;14:79–87.
  • Ooba N, Tanaka S, Yasukawa Y, et al. Effect of high potency statins on Hba1c in patients with or without diabetic mellitus. J Pharm Health Care Sci. 2016;2:8.
  • Chrysant SG. New onset diabetes mellitus induced by statins: current evidence. Postgrad Med. 2017;129:430–435.
  • Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005;19:117–125.
  • Paseban M, Butler AE, Sahebkar A. Mechanisms of statin-induced new-onset diabetes. J Cell Physiol. 2019;234(8):12551–12561.
  • Aiman U, Najmi A, Khan RA. Statin induced diabetes and its clinical implications. J Pharmacol Pharmacother. 2014;5:181–185.
  • Sonal Sekhar M, Unnikrishnan MK. South-Asian population has a higher likelihood for diabetes risk for statins regardless of potency. Med Hypotheses. 2015;84(3):283–284.
  • American Diabetes A. 2. Classification and Diagnosis of Diabetes: standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S13–S27.
  • Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–245.
  • The use of the WHO–UMC system for standardised case causality assessment. Available from: http://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf. [Last accessed on 2018 Apr 10].
  • Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49:2229–2239.
  • Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm. 1992;27:538.
  • Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl2):S1–S45.
  • Pasternak RC. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998–3007.
  • Sattar N, Preiss D, Murray HM, et al. Statin and risk of incident diabetes: A collaborative meta–analysis of randomised statin trials. Lancet. 2010;375:735–742.
  • Mora S, Glynn RJ, Hsia J, et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation. 2010;121:1069–1077.
  • Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate- dose statin therapy: A meta-analysis. JAMA. 2011;305:2556–2564.
  • Lee J, Noh Y, Shin S, et al. Impact of statins on risk of new onset diabetes mellitus: a population-based cohort study using the Korean National Health Insurance claims database. Ther Clin Risk Manag. 2016;12:1533–1543.
  • Yoon D, Sheen SS, Lee S, et al. Statins and risk of new-onset diabetes mellitus: A real-world cohort study using a clinical research data base. Medicine (Baltimore). 2016;95:5429.
  • Indumathi C, Anusha N, Vinod KV, et al. Atorvastatin Induced Adverse Drug Reactions among South Indian Tamils. J Clin Diagn Res. 2017;11:FC01–FC05.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.